ERBB3

Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors

Retrieved on: 
Tuesday, February 22, 2022
ACT, Annual report, ErbB, Relapse, Security (finance), ARC, Radiation, Company, Daratumumab, Conversation, Hope, Radiochemistry, Actinium-225, Form 10-K, Private Securities Litigation Reform Act, Astellas Pharma, Research, BMT, CD47, Partnership, Risk, AWE, RCC, Environment, Safety, U.S. Securities and Exchange Commission, CEO, ARCS, NASDAQ, Family, Toxic epidermal necrolysis, Antibody, Cancer, Adoptive cell transfer, Analysis, Patient, Financial condition report, Immunotherapy, Result, CD19, HER3, NYSE, Adult, FDA, Form 10-Q, ERBB3, Medication, SEC, Fine chemical, Vaccine, Actinium

Actinium will utilize its AWE technology platform and extensive radiotherapy know-how to conjugate one of AVEO's ErbB3 targeted antibodies, with the potent alpha-emitting radioisotope Actinium-225 (Ac-225).

Key Points: 
  • Actinium will utilize its AWE technology platform and extensive radiotherapy know-how to conjugate one of AVEO's ErbB3 targeted antibodies, with the potent alpha-emitting radioisotope Actinium-225 (Ac-225).
  • "We are excited to advance this ErbB3 targeted compound which is expressed in multiple solid tumors and is the third in the family of clinically validated ErbB targets."
  • AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development.
  • While Actinium and AVEO may elect to update these forward-looking statements at some point in the future, each of Actinium and AVEO specifically disclaims any obligation to do so.

Merus Announces Financial Results for the First Quarter and Provides Business Update

Retrieved on: 
Thursday, May 6, 2021
Tyrosine kinase receptors, Branches of biology, Cell biology, HER2/neu, Epidermal growth factor receptor, Neuregulin 1, XC2, ERBB3

Both posters present preclinical data demonstrating that the Dock & Block\xc2\xae activity of Zeno can potently inhibit NRG1 (and NRG1 fusion) signaling through HER3:HER2 and tumorigenesis.

Key Points: 
  • Both posters present preclinical data demonstrating that the Dock & Block\xc2\xae activity of Zeno can potently inhibit NRG1 (and NRG1 fusion) signaling through HER3:HER2 and tumorigenesis.
  • MCLA-129 is a Biclonics\xc2\xae, which binds to EGFR and c-MET and is being investigated for the treatment of solid tumors.
  • Dr. Geuijen has over two decades of experience in discovering and developing antibodies as medicines for clinical evaluation.
  • Merus received an upfront cash payment of $40 million, as well as an equity investment by Lilly of $20 million in Merus common shares.

AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021

Retrieved on: 
Monday, May 3, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical trials, Medical specialties, Clinical medicine, Medicine, Cancer treatments, Biotechnology, Immune system, Immunology, Monoclonal antibody, ERBB3, Mab

b'AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021 financial results on Monday, May 10, 2021.

Key Points: 
  • b'AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021 financial results on Monday, May 10, 2021.
  • AVEO\xe2\x80\x99s management team will host a conference call and audio webcast at 4:30 p.m.
  • ET on Monday, May 10, 2021, to discuss the financial results and provide a business update.\nThe call can be accessed by dialing (844) 882-7841 (U.S. and Canada) or (574) 990-9828 (international).
  • AVEO\xe2\x80\x99s earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb).

Elevation Oncology Announces the Presentation of New Preclinical Data in Pancreatic and Cholangiocarcinoma PDX Models on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling

Retrieved on: 
Saturday, April 10, 2021
Branches of biology, Tyrosine kinase receptors, Neurotrophic factors, Neuregulin 1, Proteins, ErbB, ERBB3, Neuregulin

As in prior analysis in lung and ovarian NRG1 fusion PDX models, the pan-ERBB inhibitor afatinib was used as an active control in this pancreatic PDX model.

Key Points: 
  • As in prior analysis in lung and ovarian NRG1 fusion PDX models, the pan-ERBB inhibitor afatinib was used as an active control in this pancreatic PDX model.
  • NRG1fusions have been identified in a variety of solid tumors, including lung, pancreatic, gallbladder, breast, ovarian, colorectal, neuroendocrine, cholangiocarcinomas, and sarcomas.
  • The NRG1 gene fusion is a rare genomic alteration that combines NRG1 with another partner protein to create chimeric NRG1 "fusion proteins".
  • In preclinical experiments, seribantumab prevented the activation of HER3 signaling in cells that harbor an NRG1 gene fusion.

Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Medical specialties, Immunology, Medicine, Tyrosine kinase receptors, Cancer treatments, Neurotrophic factors, HER2/neu, Monoclonal antibody therapy, Neuregulin 1, Antibody, ERBB3

All e-posters will be available on this website from Saturday, April 10 to Monday, June 21, 2021.

Key Points: 
  • All e-posters will be available on this website from Saturday, April 10 to Monday, June 21, 2021.
  • The posters will also be available on the Merus website as of Saturday, April 10, 2021.
  • In preclinical studies, Zeno also potently inhibits HER2/HER3 heterodimer formation and tumor growth in models harboring NRG1 fusions.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics .

Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-driven Precision Medicine to Accelerate Clinical Development of HMBD-001 In HER3 Driven Cancers

Retrieved on: 
Monday, December 14, 2020
Branches of biology, Tyrosine kinase receptors, Immunology, Antibodies, Neutralizing antibody, ERBB3, Biology, Biochemistry

[1]

Key Points: 
  • [1]
    HMBD-001 is a uniquely differentiated anti-HER3 neutralizing antibody that was developed using Hummingbird's proprietary Rational Antibody Discovery platform.
  • HMBD-001 has been immune-engineered to bind with high affinity to the HER3 dimerization interface and block HER3 growth signals to the cancer.
  • Most importantly, HMBD-001 uniquely blocks HER3 in both open and closed conformations, and in the presence or absence of high concentrations of NRG1.
  • Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.

Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation

Retrieved on: 
Tuesday, July 28, 2020
Tyrosine kinase receptors, Oncogenes, Branches of biology, Cancer, Clinical medicine, HER2/neu, Epidermal growth factor receptor, ErbB, Quinazolines, Fast track, ERBB3, Gefitinib

More information about FDA Fast Track designation can be found at www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approva... .

Key Points: 
  • More information about FDA Fast Track designation can be found at www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approva... .
  • These mutations include extracellular domain allosteric mutations of HER2, as well as EGFR and HER2 kinase domain exon 20 insertions, and additional activating oncogenic drivers of ErbB.
  • Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Global Pipeline Insight Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 6, 2019
Biotechnology, Pharmaceutical, Health, Tyrosine kinase receptors, Branches of biology, Oncogenes, Cell biology, Epidermal growth factor receptor, ErbB, ERBB4, ERBB3, Receptor tyrosine kinase

The "Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies

Retrieved on: 
Tuesday, November 5, 2019
Tyrosine kinase receptors, Branches of biology, Cancer, Medicine, Fibroblast growth factor receptor 1, KRAS, Tyrosine kinase, Fibroblast growth factor receptor 2, ErbB, ERBB3, Pancreatic cancer, HER2/neu

The study will enroll patients with activating mutations, amplifications or fusions in HER2, ERBB3, FGFR1, or FGFR2 receptor tyrosine kinases, or any KRAS mutation subtype.

Key Points: 
  • The study will enroll patients with activating mutations, amplifications or fusions in HER2, ERBB3, FGFR1, or FGFR2 receptor tyrosine kinases, or any KRAS mutation subtype.
  • It will also include pancreatic adenocarcinoma with no molecular typing since the large majority of those patients harbor a KRAS mutation.
  • Zotatifin will be administered as a monotherapy in weekly intravenous infusions in subjects with advanced solid tumor malignancies.
  • The drug is currently being evaluated in a Phase 1/2 clinical trial in patients with solid tumors.

Black Diamond Therapeutics Presents Data From its Program Targeting Oncogenic Allosteric Mutations in EGFR for Glioblastoma as Late Breaker at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, March 29, 2019
Tyrosine kinase receptors, Oncogenes, Branches of biology, Carcinogenesis, Epidermal growth factor receptor, ErbB, Cancer, ERBB3

Title: Epidermal Growth Factor Receptor Oncogenes Expressed in Glioblastoma are Activated as Covalent Dimers and Exhibit Unique Pharmacology.

Key Points: 
  • Title: Epidermal Growth Factor Receptor Oncogenes Expressed in Glioblastoma are Activated as Covalent Dimers and Exhibit Unique Pharmacology.
  • LoDi-EGFR mutant oncogenes are the first subset of allosteric mutant ErbB oncogenes to be described by Black Diamond Therapeutics.
  • The prevalence of the allosteric mutations in ErbB ranges from two to 15 percent of patients diagnosed with a given tumor type.
  • Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations.